{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:12:16Z","timestamp":1788541936002,"version":"build-2803163510"},"reference-count":108,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Fabry disease is a rare X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene, resulting in deficient \u03b1-galactosidase A activity and progressive accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3). Although lysosomal substrate storage represents the primary molecular defect, accumulating evidence indicates that disease progression is driven by interconnected mechanisms, including chronic inflammation, oxidative stress, endothelial dysfunction, and impaired autophagy, leading to progressive multisystem involvement. The marked clinical heterogeneity of Fabry disease, together with nonspecific early manifestations, frequently delays diagnosis and complicates patient stratification and therapeutic decision-making. While advances in biomarkers, genetic testing, and imaging have improved disease recognition, current diagnostic approaches remain insufficient to fully capture disease complexity. Precision medicine is therefore emerging as a promising strategy through the integration of clinical, molecular, imaging, and multi-omics data. In this context, artificial intelligence (AI) offers novel opportunities for early diagnosis, biomarker discovery, risk stratification, and prediction of therapeutic response. This review provides an integrated overview of the molecular mechanisms, inflammatory pathways, clinical manifestations, and precision diagnostic strategies underlying Fabry disease, highlighting how AI-driven approaches may accelerate the transition toward more accurate, personalized, and predictive disease management.<\/jats:p>","DOI":"10.3390\/cells15171614","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:07:32Z","timestamp":1788538052000},"page":"1614","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fabry Disease: Integrating Molecular Pathophysiology, Precision Diagnosis, and Artificial Intelligence Toward Precision Medicine"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3335-1726","authenticated-orcid":false,"given":"Giuseppa","family":"Biddeci","sequence":"first","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9767-679X","authenticated-orcid":false,"given":"Gaetano","family":"Spinelli","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2470-7030","authenticated-orcid":false,"given":"Paolo","family":"Colomba","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Anania","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Duro","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8085-7538","authenticated-orcid":false,"given":"Francesco","family":"Di Blasi","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Thompson, S.E., Roy, A., Geberhiwot, T., Gehmlich, K., and Steeds, R.P. (2025). Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies. Biomedicines, 13.","DOI":"10.3390\/biomedicines13030624"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pcad.2025.08.003","article-title":"Fabry disease cardiomyopathy: A state-of-the-art review","volume":"92","author":"Pande","year":"2025","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry\u2019s disease","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Zhang, M., and Wang, C. (2025). Therapeutic landscape of Fabry disease: Advances and challenges from classical strategies to emerging therapies. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1662867"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Faro, D.C., Di Pino, F.L., and Monte, I.P. (2024). Inflammation, Oxidative Stress, and Endothelial Dysfunction in the Pathogenesis of Vascular Damage: Unraveling Novel Cardiovascular Risk Factors in Fabry Disease. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25158273"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"La Russa, A., Siniscalchi, A., Bonaventura, A., Di Noia, D., Valsania, T., Stallone, G., Tartaglia, L., Chiapparino, C., Di Rienzo, G., and Coppolino, G. (2025). Potential Pathogenetic Role of the D313Y Mutation in the GLA Gene in Anderson Fabry Disease: Two Case Reports. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26094400"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1007\/s11255-024-04042-4","article-title":"Fabry disease: A rare disorder calling for personalized medicine","volume":"56","author":"Lerario","year":"2024","journal-title":"Int. Urol. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Olszewska, M., Schwermer, K., and Pawlaczyk, K. (2025). Newborn Screening in Fabry Disease. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262412125"},{"key":"ref_10","first-page":"5548445","article-title":"Anderson\u2013Fabry Disease: From Endothelial Dysfunction to Emerging Therapies","volume":"2021","author":"Stamerra","year":"2021","journal-title":"Adv. Pharmacol. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Viggiano, E., and Politano, L. (2021). X Chromosome Inactivation in Carriers of Fabry Disease: Review and Meta-Analysis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147663"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/08035320600618809","article-title":"Disease manifestations and X inactivation in heterozygous females with Fabry disease","volume":"95","author":"Maier","year":"2006","journal-title":"Acta Paediatr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Biddeci, G., Spinelli, G., Colomba, P., Duro, G., Anania, M., Francofonte, D., and Di Blasi, F. (2025). Fabry Disease and Inflammation: Potential Role of p65 iso5, an Isoform of the NF-\u03baB Complex. Cells, 14.","DOI":"10.3390\/cells14030230"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Biddeci, G., Spinelli, G., Colomba, P., Duro, G., Giacalone, I., and Di Blasi, F. (2025). Fabry Disease Beyond Storage: The Role of Inflammation in Disease Progression. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26157054"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Coelho-Ribeiro, B., Silva, H.G., Sampaio-Marques, B., Fraga, A.G., Azevedo, O., Pedrosa, J., and Ludovico, P. (2024). Inflammation and Exosomes in Fabry Disease Pathogenesis. Cells, 13.","DOI":"10.3390\/cells13080654"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s13023-025-03922-x","article-title":"Fabry disease in females: Organ involvement and clinical outcomes compared with the general population (103\/150 characters)","volume":"20","author":"Hopkin","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kurdi, H., Lavalle, L., Moon, J.C.C., and Hughes, D. (2024). Inflammation in Fabry disease: Stages, molecular pathways, and therapeutic implications. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1420067"},{"key":"ref_19","first-page":"26330040251375498","article-title":"Systemic inflammation in Fabry disease: A longitudinal immuno-genetic analysis based on variant stratification","volume":"6","year":"2025","journal-title":"Ther. Adv. Rare Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","article-title":"Contribution of inflammatory pathways to Fabry disease pathogenesis","volume":"122","author":"Rozenfeld","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","article-title":"Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells","volume":"95","author":"Shen","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/jimd.12228","article-title":"Developments in the treatment of Fabry disease","volume":"43","author":"Hollak","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Beir\u00e3o, I., Cabrita, A., Torres, M., Silva, F., Aguiar, P., Laranjeira, F., and Gomes, A.M. (2017). Biomarkers and Imaging Findings of Anderson-Fabry Disease-What We Know Now. Diseases, 5.","DOI":"10.3390\/diseases5020015"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Carnicer-C\u00e1ceres, C., Arranz-Amo, J.A., Cea-Arestin, C., Camprodon-Gomez, M., Moreno-Martinez, D., Lucas-Del-Pozo, S., Molt\u00f3-Abad, M., Tigri-Santi\u00f1a, A., Agraz-Pamplona, I., and Rodriguez-Palomares, J.F. (2021). Biomarkers in Fabry Disease. Implications for Clinical Diagnosis and Follow-up. J. Clin. Med., 10.","DOI":"10.3390\/jcm10081664"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"106032","DOI":"10.1016\/j.jddst.2024.106032","article-title":"Fabry disease management: Current status, therapeutic challenges, and future horizons in drug delivery and artificial intelligence assisted diagnosis","volume":"100","author":"Raj","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Simonetta, I., Tuttolomondo, A., Daidone, M., and Pinto, A. (2020). Biomarkers in Anderson-Fabry Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218080"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13023-025-03655-x","article-title":"Applying artificial intelligence to rare diseases: A literature review highlighting lessons from Fabry disease","volume":"20","author":"Germain","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5582\/irdr.2023.01111","article-title":"The use of artificial intelligence in the treatment of rare diseases: A scoping review","volume":"13","author":"He","year":"2024","journal-title":"Intractable Rare Dis. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e55001","DOI":"10.2196\/55001","article-title":"Medical Expert Knowledge Meets AI to Enhance Symptom Checker Performance for Rare Disease Identification in Fabry Disease: Mixed Methods Study","volume":"4","author":"Pankow","year":"2025","journal-title":"JMIR AI"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The Molecular Defect Leading to Fabry Disease: Structure of Human \u03b1-Galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J. Mol. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13023-019-1274-3","article-title":"Correlation between GLA variants and alpha-Galactosidase A profile in dried blood spot: An observational study in Brazilian patients","volume":"15","author":"Varela","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Jehn, U., Bayraktar, S., Pollmann, S., Van Marck, V., Weide, T., Pavenst\u00e4dt, H., Brand, E., and Lenders, M. (2021). \u03b1-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111339"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Giacalone, I., Ruzzi, L., Anania, M., Cuonzo, M., Marsana, E.M., Mastrippolito, S., Francofonte, D., Bucco, S., D\u2019Errico, A., and Longo, M.O. (2025). The Identification of a Novel Pathogenic Variant of the GLA Gene Associated with a Classic Phenotype of Anderson\u2013Fabry Disease: A Clinical and Molecular Study. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26020470"},{"key":"ref_34","first-page":"100926","article-title":"\u03b1-Gal A missense variants associated with Fabry disease can lead to ER stress and induction of the unfolded protein response","volume":"33","author":"Consolato","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Duro, G., Zizzo, C., Cammarata, G., Burlina, A., Burlina, A., Polo, G., Scalia, S., Oliveri, R., Sciarrino, S., and Francofonte, D. (2018). Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19123726"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejim.2016.03.015","article-title":"The impact of fever\/hyperthermia in the diagnosis of Fabry: A retrospective analysis","volume":"32","author":"Verrecchia","year":"2016","journal-title":"Eur. J. Intern. Med."},{"key":"ref_37","first-page":"e30989","article-title":"Late-Onset Fabry Disease Affecting the Kidneys and Liver While Sparing the Heart: A Case Report","volume":"14","author":"Alitter","year":"2022","journal-title":"Cureus"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s-Saladelafont, E., Fern\u00e1ndez-Mart\u00edn, J., and Ortolano, S. (2023). Fabry Disease and Central Nervous System Involvement: From Big to Small, from Brain to Synapse. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065246"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s44325-025-00058-6","article-title":"Cardiac manifestations of Fabry disease","volume":"2","author":"Dougherty","year":"2025","journal-title":"npj Cardiovasc. Health"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s13023-025-03791-4","article-title":"Late-onset fabry disease presenting with unexplained renal failure, left ventricular hypertrophy, and recurrent syncope: A case report","volume":"20","author":"Ying","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"504784","DOI":"10.1155\/2015\/504784","article-title":"High variability of Fabry disease manifestations in an extended Italian family","volume":"2015","author":"Cammarata","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.gene.2012.06.013","article-title":"X-inactivation in Fabry disease","volume":"505","author":"Elstein","year":"2012","journal-title":"Gene"},{"key":"ref_43","first-page":"2","article-title":"Fabry disease in women: Beyond the role of \u201ccarriers\u201d","volume":"4","author":"Rosario","year":"2025","journal-title":"Rare Dis. Orphan Drugs J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/TACG.S146022","article-title":"Multiple phenotypic domains of Fabry disease and their relevance for establishing genotype- phenotype correlations","volume":"12","author":"Oliveira","year":"2019","journal-title":"Appl. Clin. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"61415","DOI":"10.18632\/oncotarget.18250","article-title":"Inter-familial and intra-familial phenotypic variability in three Sicilian families with Anderson-Fabry disease","volume":"8","author":"Tuttolomondo","year":"2017","journal-title":"Oncotarget"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"Togawa","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00395-022-00930-x","article-title":"Blunting TRPML1 channels protects myocardial ischemia\/reperfusion injury by restoring impaired cardiomyocyte autophagy","volume":"117","author":"Xing","year":"2022","journal-title":"Basic Res. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ivanova, M.M., Changsila, E., Iaonou, C., and Goker-Alpan, O. (2019). Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210617"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Liebau, M.C., Braun, F., H\u00f6pker, K., Weitbrecht, C., Bartels, V., M\u00fcller, R.U., Brodesser, S., Saleem, M.A., Benzing, T., and Schermer, B. (2013). Dysregulated autophagy contributes to podocyte damage in Fabry\u2019s disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063506"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Rydzek, J., Muzyka, A., Majcherczyk, K., Soczy\u0144ska, J., Gawe\u0142czyk, W., \u017bo\u0142yniak, M., and Wo\u017aniak, S. (2026). Fabry Disease: A Focus on the Role of Oxidative Stress. Antioxidants, 15.","DOI":"10.3390\/antiox15020168"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Ravarotto, V., Carraro, G., Pagnin, E., Bertoldi, G., Simioni, F., Maiolino, G., Martinato, M., Landini, L., Davis, P.A., and Cal\u00f2, L.A. (2018). Oxidative stress and the altered reaction to it in Fabry disease: A possible target for cardiovascular-renal remodeling?. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0204618"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Simonetta, I., Baglio, I., and Tuttolomondo, A. (2026). Molecular, Metabolic and Inflammatory Patterns Involved in Pathogenesis of Anderson-Fabry Disease. Cells, 15.","DOI":"10.3390\/cells15050443"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"i51","DOI":"10.1093\/eurheartjsupp\/suae104","article-title":"Cardiac involvement in Fabry disease: Recent advances, unresolved issues, and unmet needs","volume":"27","author":"Pieroni","year":"2025","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11897-024-00645-1","article-title":"Fabry Disease: Cardiac Implications and Molecular Mechanisms","volume":"21","author":"Weissman","year":"2024","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Levstek, T., Vujkovac, B., and Trebusak Podkrajsek, K. (2020). Biomarkers of Fabry Nephropathy: Review and Future Perspective. Genes, 11.","DOI":"10.3390\/genes11091091"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e20240035","DOI":"10.1590\/2175-8239-jbn-2024-0035en","article-title":"The role of podocyte injury in the pathogenesis of Fabry disease nephropathy","volume":"46","author":"Kirsztajn","year":"2024","journal-title":"J. Bras. Nefrol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Muntean, C., Starcea, I.M., Stoica, C., and Banescu, C. (2022). Clinical Characteristics, Renal Involvement, and Therapeutic Options of Pediatric Patients With Fabry Disease. Front. Pediatr., 10.","DOI":"10.3389\/fped.2022.908657"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1159\/000492593","article-title":"Systematic DNA Study for Fabry Disease in the End Stage Renal Disease Patients from a Southern Italy Area","volume":"43","author":"Zizzo","year":"2018","journal-title":"Kidney Blood Press. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/1346-8138.17690","article-title":"Cutaneous manifestations of Fabry disease: A systematic review","volume":"52","author":"Folkmann","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/STROKEAHA.114.006283","article-title":"Cerebrovascular Involvement in Fabry Disease: Current Status of Knowledge","volume":"46","author":"Burlina","year":"2015","journal-title":"Stroke"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Burlina, A.P., Sims, K.B., Politei, J.M., Bennett, G.J., Baron, R., Sommer, C., M\u00f8ller, A.T., and Hilz, M.J. (2011). Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: The report of an expert panel. BMC Neurol., 11.","DOI":"10.1186\/1471-2377-11-61"},{"key":"ref_62","first-page":"9","article-title":"Cerebrovascular disorders and Fabry disease","volume":"3","author":"Reisin","year":"2024","journal-title":"Rare Dis. Orphan Drugs J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13023-018-0882-7","article-title":"Characterization of vertigo and hearing loss in patients with Fabry disease","volume":"13","author":"Schneider","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_64","first-page":"e12083","article-title":"Stroke and Fabry Disease: A Review of Literature","volume":"12","author":"Mishra","year":"2020","journal-title":"Cureus"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"20","DOI":"10.20517\/rdodj.2024.13","article-title":"Neuropathy and pain in Fabry disease","volume":"3","author":"Medala","year":"2024","journal-title":"Rare Dis. Orphan Drugs J."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Caputo, F., Lungaro, L., Galdi, A., Zoli, E., Giancola, F., Caio, G., De Giorgio, R., and Zoli, G. (2021). Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18063320"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Xavier de \u00c1vila, D., and Villacorta Junior, H. (2023). Dermatological Manifestations in Fabry Disease. Amyloidosis and Fabry Disease, Springer.","DOI":"10.1007\/978-3-031-17759-0"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2027852","DOI":"10.1080\/19490976.2022.2027852","article-title":"Fabry disease\u2014A multisystemic disease with gastrointestinal manifestations","volume":"14","author":"Lenders","year":"2022","journal-title":"Gut Microbes"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1742-1241.2006.01061.x","article-title":"Hyperhidrosis: A new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey","volume":"60","author":"Lidove","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Tuttolomondo, A., Chimenti, C., Cianci, V., Gallieni, M., Lanzillo, C., La Russa, A., Limongelli, G., Mignani, R., Olivotto, I., and Pieruzzi, F. (2025). Females with Fabry disease: An expert opinion on diagnosis, clinical management, current challenges and unmet needs. Front. Cardiovasc. Med., 12.","DOI":"10.3389\/fcvm.2025.1536114"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Amodio, F., Caiazza, M., Monda, E., Rubino, M., Capodicasa, L., Chiosi, F., Simonelli, V., Dongiglio, F., Fimiani, F., and Pepe, N. (2022). An Overview of Molecular Mechanisms in Fabry Disease. Biomolecules, 12.","DOI":"10.3390\/biom12101460"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Monte, M.A., Veroux, M., Rodolico, M.S., Losi, V., Di Pino, L., Bella, R., Lanza, G., and Monte, I.P. (2022). Fabry\u2019s Disease: The Utility of a Multidisciplinary Screening Approach. Life, 12.","DOI":"10.3390\/life12050623"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"177038","DOI":"10.1016\/j.ejphar.2024.177038","article-title":"The NF-\u03baB pathway: Key players in neurocognitive functions and related disorders","volume":"984","author":"Yang","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13023-022-02215-x","article-title":"Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: A multidisciplinary Turkey perspective","volume":"17","author":"Ezgu","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Gragnaniello, V., Burlina, A.P., Polo, G., Giuliani, A., Salviati, L., Duro, G., Cazzorla, C., Rubert, L., Maines, E., and Germain, D.P. (2021). Newborn Screening for Fabry Disease in Northeastern Italy: Results of Five Years of Experience. Biomolecules, 11.","DOI":"10.3390\/biom11070951"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"130","DOI":"10.15171\/jnp.2017.22","article-title":"Fabry disease; early diagnosis improves prognosis but diagnosis is often delayed","volume":"6","author":"Jamboti","year":"2017","journal-title":"J. Nephropathol."},{"key":"ref_77","first-page":"101245","article-title":"Evaluation of GLA variants detected in newborn screening for Fabry disease using biomarker analysis","volume":"44","author":"Sawada","year":"2025","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Duro, G., Anania, M., Zizzo, C., Francofonte, D., Giacalone, I., D\u2019Errico, A., Marsana, E.M., and Colomba, P. (2024). Diagnosis of Fabry Disease Using Alpha-Galactosidase A Activity or LysoGb3 in Blood Fails to Identify Up to Two Thirds of Female Patients. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25105158"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s40246-024-00697-3","article-title":"Long-read sequencing enables comprehensive molecular genetic diagnosis of Fabry disease","volume":"18","author":"Yao","year":"2024","journal-title":"Hum. Genom."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1159\/000541207","article-title":"Fabry Disease with Genetic Variants of Unknown Significance and Concomitant Immunoglobulin A Nephropathy","volume":"49","author":"Zhou","year":"2024","journal-title":"Kidney Blood Press. Res."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Lee, S.Y., Kim, I.Y., Ahn, S.-H., Kim, S.J., Lee, H.-M., Lee, J.E., Byeon, G.-J., Ko, H.-C., Lee, H.J., and Choi, S. (2025). Multidisciplinary Care Model as a Center of Excellence for Fabry Disease: A Practical Guide to Diagnosis and Management by Clinical Specialty in South Korea. J. Clin. Med., 14.","DOI":"10.3390\/jcm14134400"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e240501","DOI":"10.1148\/ryct.240501","article-title":"Native T1 Mapping at Cardiac MRI: A Biomarker for Quantifying Glycosphingolipid Accumulation Severity in Fabry Disease","volume":"8","author":"Marchitelli","year":"2026","journal-title":"Radiol. Cardiothorac. Imaging"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2054358120985627","DOI":"10.1177\/2054358120985627","article-title":"Renal Manifestations of Fabry Disease: A Narrative Review","volume":"8","author":"Silva","year":"2021","journal-title":"Can. J. Kidney Health Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.trsl.2023.02.006","article-title":"Deep next-generation proteomics and network analysis reveal systemic and tissue-specific patterns in Fabry disease","volume":"258","author":"Tebani","year":"2023","journal-title":"Transl. Res."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Chantada-V\u00e1zquez, M.d.P., Bravo, S.B., Barbosa-Gouveia, S., Alvarez, J.V., and Couce, M.L. (2022). Proteomics in Inherited Metabolic Disorders. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314744"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Rocchetti, M.T., Spadaccino, F., Catalano, V., Zaza, G., Stallone, G., Fiocco, D., Netti, G.S., and Ranieri, E. (2022). Metabolic Fingerprinting of Fabry Disease: Diagnostic and Prognostic Aspects. Metabolites, 12.","DOI":"10.3390\/metabo12080703"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"27869","DOI":"10.1021\/acsomega.5c00894","article-title":"Untargeted Lipidomics in Fabry Disease of Urine Samples by Low-Resolution Flow Injection Mass Spectrometry (ESI(\u00b1)-LTQ MS)","volume":"10","author":"Foletto","year":"2025","journal-title":"ACS Omega"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"119833","DOI":"10.1016\/j.cca.2024.119833","article-title":"Plasma and platelet lipidome changes in Fabry disease","volume":"562","author":"Burla","year":"2024","journal-title":"Clin. Chim. Acta"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"102314","DOI":"10.1016\/j.genrep.2025.102314","article-title":"The transformative role of Artificial Intelligence in genomics: Opportunities and challenges","volume":"41","author":"Dara","year":"2025","journal-title":"Gene Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"104041","DOI":"10.1016\/j.gimo.2026.104041","article-title":"P550: Predicting pathogenicity in Fabry disease: Longitudinal analysis of GLA variant reclassification and trajectories (2023\u20132025)*","volume":"4","author":"Kozaric","year":"2026","journal-title":"Genet. Med. Open"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Rroji, M., Figurek, A., and Spasovski, G. (2023). Proteomic Approaches and Potential Applications in Autosomal Dominant Polycystic Kidney Disease and Fabry Disease. Diagnostics, 13.","DOI":"10.3390\/diagnostics13061152"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s44162-025-00128-4","article-title":"Study based on electronic Health recOrds to identify Patients at high-risk of fabry diseasE\u2014HOPE","volume":"4","author":"Ghosn","year":"2025","journal-title":"J. Rare Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1186\/s13023-021-02150-3","article-title":"A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithm","volume":"16","author":"Jefferies","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Michalski, A.A., Lis, K., Stankiewicz, J., Kloska, S.M., Sycz, A., Dudzi\u0144ski, M., Muras-Szwedziak, K., Nowicki, M., Bazan-Socha, S., and Dabrowski, M.J. (2023). Supporting the Diagnosis of Fabry Disease Using a Natural Language Processing-Based Approach. J. Clin. Med., 12.","DOI":"10.3390\/jcm12103599"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Hahn, P., Lechner, W., Siefen, R.G., Lampe, C., Nordbeck, P., Grigull, L., and L\u00fccke, T. (2025). Improving a data mining based diagnostic support tool for rare diseases on the example of M. Fabry: Gender differences need to be taken into account. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0326372"},{"key":"ref_96","first-page":"100921","article-title":"Automated urinary sediment detection for Fabry disease using deep-learning algorithms","volume":"33","author":"Uryu","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1038\/s41598-026-35466-w","article-title":"Zebra bodies recognition by artificial intelligence (ZEBRA): A computational tool for Fabry nephropathy","volume":"16","author":"Cazzaniga","year":"2026","journal-title":"Sci. Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13023-025-03627-1","article-title":"Deep learning assisted retinal microvasculature assessment and cerebral small vessel disease in Fabry disease","volume":"20","author":"Li","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e26599","DOI":"10.1002\/hbm.26599","article-title":"Assessing brain involvement in Fabry disease with deep learning and the brain-age paradigm","volume":"45","author":"Montella","year":"2024","journal-title":"Hum. Brain Mapp."},{"key":"ref_100","first-page":"101152","article-title":"Using artificial intelligence and promoter-level transcriptome analysis to identify a biomarker as a possible prognostic predictor of cardiac complications in male patients with Fabry disease","volume":"41","author":"Kobayashi","year":"2024","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40259-025-00723-3","article-title":"Progress and Challenges in the Treatment of Fabry Disease","volume":"39","author":"Lenders","year":"2025","journal-title":"BioDrugs"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2174\/1570159X20666220601124117","article-title":"Fabry Disease: Current and Novel Therapeutic Strategies. A Narrative Review","volume":"21","author":"Palaiodimou","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"100927","DOI":"10.1016\/j.xkme.2024.100927","article-title":"Artificial Intelligence in Nephrology: Clinical Applications and Challenges","volume":"7","author":"Singh","year":"2025","journal-title":"Kidney Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"102877","DOI":"10.1016\/j.cpcardiol.2024.102877","article-title":"Artificial intelligence electrocardiography for the evaluation of cardiac involvement in Fabry disease","volume":"50","author":"Abbasi","year":"2025","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e73612","DOI":"10.2196\/73612","article-title":"Artificial Intelligence, Connected Care, and Enabling Digital Health Technologies in Rare Diseases With a Focus on Lysosomal Storage Disorders: Scoping Review","volume":"28","author":"Spreafico","year":"2026","journal-title":"J. Med. Internet Res."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Abbas, Q., Jeong, W., and Lee, S.W. (2025). Explainable AI in Clinical Decision Support Systems: A Meta-Analysis of Methods, Applications, and Usability Challenges. Healthcare, 13.","DOI":"10.3390\/healthcare13172154"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"7","DOI":"10.32628\/IJSRST25126288","article-title":"Explainable AI (XAI) in Healthcare: Building Trust in Medical Diagnosis Systems","volume":"12","author":"Khade","year":"2025","journal-title":"Int. J. Sci. Res. Sci. Technol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Weiner, E.B., Dankwa-Mullan, I., Nelson, W.A., and Hassanpour, S. (2025). Ethical challenges and evolving strategies in the integration of artificial intelligence into clinical practice. PLoS Digit. Health, 4.","DOI":"10.1371\/journal.pdig.0000810"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/17\/1614\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:15:32Z","timestamp":1788538532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/17\/1614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":108,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cells15171614"],"URL":"https:\/\/doi.org\/10.3390\/cells15171614","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]}}}